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The requirement for glycosylation in the transmembrane protein, gp41, of human immunodeficiency virus type 1 envelope
protein for fusion activity has been studied. By using a mutant gene in which three conserved sites have been removed and
which shows no fusion ability, genes were constructed which replace one, two, or three sites in all possible combinations.
Following expression of the resultant proteins using the vaccinia T7 system, each Env variant was assessed by visual and
quantitative syncytium assays. Our data indicate that two sites are sufficient for high levels of fusion and that the single site
at position 621 is the most critical of all positions. We interpret our data in the light of previous contradictory reports on the
role of gp41 glycosylation in bioactivity and the emerging structure of gp41. © 1998 Academic Press
INTRODUCTION
The envelope glycoprotein (Env) of human immunode-
ficiency virus type 1 (HIV-1) is an oligomer composed of
extracellular (gp120) and transmembrane (gp41) glyco-
proteins (Gallaher et al., 1989; Kowalski et al., 1987). The
gp120 subunits are responsible for the adsorption of
virions to CD4 and chemokine receptors on the host
cells, whereas the gp41 mediates fusion of the virus and
cell membrane (Moore and Sweet, 1993). Since Env is
required for infectivity and is the target for neutralizing
antibodies, the structure, assembly pathway, and func-
tion of Env are the subjects of intense investigation. The
Env precursor gp160 is a type I integral membrane pro-
tein that becomes heavily glycosylated in the lumen of
the endoplasmic reticulum where disulfide bond forma-
tion also occurs (Stein and Engleman, 1990; Willey et al.,
1988). The folding of gp160 necessary for CD4 binding
and oligomerization occurs either in the endoplasmic
reticulum or during transit to the Golgi complex and may
involve chaperone binding dependent upon the glycosy-
lation state of Env (Otteken et al., 1996). Subsequently,
Env is proteolytically cleaved by a host protease, most
likely in a late Golgi compartment, to yield noncovalently
linked gp120 and gp41 which are transported to the
plasma membrane. At the cell surface, three scenarios
are possible: (i) due to the weak association of gp120
and gp41, gp120 protein maybe released into the medium
leaving a gp41 of unknown function; (ii) cell surface
expressed gp120–gp41 complexes may bind CD4 on
uninfected lymphocytes, resulting in the fusion of cells
and consequent syncytium formation; (iii) gp120–gp41
complexes may be picked up on emerging virus particles
when HIV buds and thus equip the virion for infection of
new CD41 cells (Ratner, 1992).
The glycosylation of Env is extensive, with glycans
representing 50% of the molecular mass of the mature
gp120 (Geyer et al., 1988) and reports from as early as
1987 indicated that N-glycosylation was important for
HIV infectivity in that the treatment of HIV infected lym-
phocyte culture with certain inhibitors of the early glyco-
sylation steps (tunicamycin, deoxynojirimycin) prevent
syncytium formation (Fenouillet et al., 1994; Gruters et al.,
1987; Ratner, 1992). In contrast, inhibitors of the later
glycosylation steps (including Mannose trimming) and in
vitro deglycosylation of mature HIV had no significant
effect on infectivity (Fenouillet et al., 1994; Ratner, 1992).
A variety of additional experimental approaches have
also indicated that glycosylation is important for Env
function (summarized in Fenouillet et al., 1994; Ratner,
1992). For example, in the case of gp120 the removal of
three glycosylation sites present in V4–C5 region either
altered the conformation of gp120 as measured by bind-
ing of a neutralizing antibody (Hemming et al., 1996) or
reduced CD4 binding (Dirckx et al., 1990). Together,
these results have been interpreted to suggest that in-
dividual glycosylation-site removal rarely disrupts func-
tion significantly but that combinations of mutation that
lead to a reduction of glycosylation as a whole may
substantially alter Env function (Fenouillet et al., 1994).
In contrast with gp120, the gp41 ectodomain is rela-
tively poorly glycosylated with only four or five potential
glycosylation sites (Chakrabarti et al., 1987; Dedera et al.,
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1992; Fenouillet et al., 1993; Lee et al., 1992). These sites
are all included within a 30 residue stretch of the mole-
cule in which three important functional domains have
been mapped: (i) the precursor gp160 proteolytic cleav-
age site; (ii) the immunodominant epitope of gp41; and
(iii) the gp41 fusion peptide (Moore and Sweet, 1993).
The role of gp41 glycans has been studied by several
groups using glycosylation site mutation and apparently
conflicting results have been obtained. Dedera et al.
(1992) showed that the mutation Asn-616 and Asn-621
attenuated syncytium formation. In contrast, Lee et al.
(1992) showed that the removal of the glycosylation site
corresponding to Asn-642 caused a reduction in infec-
tivity, and both Cao et al. (1993) and Dash et al. (1994)
reported that lack of this site prevented syncytium for-
mation. In addition, Cao et al. (1993) showed that the
glycosylation site at position Asn-630 was also important
for synctium formation. Therefore, the extent to which
any single glycosylation site in gp41 affects Env bioac-
tivity remains uncertain and appears to be dependent on
the experimental procedures used. There is no doubt
that glycans have a role, however, as complete removal
of the glycan clusters from gp41 (comprising the three
N-linked glycosylation sites at Asn-621, Asn-630, and
Asn-642) abrogated the ability of Env to mediate fusion
entirely (Fenouillet et al., 1993).
As the removal of three glycosylation sites provided for
the complete abolition of Env function we have used this
carbohydrate negative mutant of gp41 to rebuild each
single glycosylation site (at Asn-621 or Asn-630 or Asn-
642) and combinations of two glycosylation sites (Asn-
621/Asn-630 or Asn-621/Asn-642 or Asn-630/Asn-642) to
determine the minimum glycan requirement for the func-
tion of gp160. In addition, to allow us to assess if the
exact position of the carbohydrate side chain is impor-
tant or if merely the presence of carbohydrate padding
generally in the region is sufficient, we also introduced a
novel single glycosylation site at position 637, displaced
by several amino acids from the original Asn-630 or
Asn-642. Each mutant was expressed in Hela T4 cells
using vaccinia virus and assessed for Env expression,
Env cleavage, and the ability to mediate syncytium for-
mation. Our results are interpreted in light of the emerg-
ing models of the gp41 domain (Chan et al., 1997; Lu et
al., 1995).
RESULTS
Expression of mutant envelopes carrying
reconstructed glycosylation sites
In order to assess the role of individual glycosylation
sites in the processing and bioactivity of gp160, we used
our previously characterized mutant lacking the three
glycosylation sites at positions 621, 630, and 642 (Fe-
nouillet et al., 1993) as a null background for the recon-
struction of a variety of glycosylation genotypes (Fig. 1).
In order to confirm that mutation of the conserved N-
linked glycosylation sites had not affected the expres-
sion of Env, each mutant protein was expressed using
the vaccinia T7 system (Fuerst et al., 1986) in which
HeLaT4 cells were transfected with plasmids encoding
either wild-type or mutant envelope under control of the
T7 promoter. At 72 h posttransfection, cells were har-
vested, lysed, and analyzed by SDS–polyacrylamide gel
electrophoresis (PAGE) and Western blot using monoclo-
nal antibody NEA9303 specific for the gp41 domain. The
Env precursor gp160 was detected in all samples with
the exception of reconstruction N637/642, which consis-
tently gave lower expression levels than the remaining
mutants (Fig. 2). The gp41 encoded by N637 exhibited
reduced migration when compared to N0 consistent with
carbohydrate occupation of the added site. In addition, in
both wild-type and mutant envelope glycoproteins, gp160
was cleaved to yield gp41 and gp120 (not detected by
NEA9303). The ratio of the gp160 to gp41 signal on these
blots is a measure of the efficiency of Env cleavage and
did not vary substantially between the mutants analyzed
despite the varied total expression level observed. In
each mutant sample, the gp41 species detected follow-
ing expression showed an increase in mobility when
compared with the wild-type form and corresponded to
the absence of one or more oligosaccharide chains at
the glycosylation sites in keeping with the mutations
made.
HIV-1 Env-mediated cell fusion
The results of Env expression and cleavage suggested
that the Env biosynthetic pathway, as measured by the
processing of gp160 up to and including the late cleav-
age reaction, was not substantially affected by the gly-
cosylation site mutations made. Therefore, in order to
test whether membrane bound gp41 carrying specific
glycan additions had regained the ability to induce mem-
brane fusion following gp120 binding to CD4, two types
of syncytium assay were performed. In the first, HeLaT4
cells were infected with vTF7-3 and transfected with
plasmids encoding either wild-type or mutant envelope
sequences. At 18 h posttransfection, cells were fixed and
scored for syncytium activity by light microscopy. The
parental phenotype gp160 lacking all three glycosylation
sites did not induce syncytium formation as previously
reported (Fenouillet et al., 1993). Mutants with recon-
structed glycosylation sites at N630 or N642 also failed
to induce syncytia in this assay (Fig. 3). However, syncy-
tium formation was observed when cells were trans-
fected with either 160WT envelope plasmid or recon-
structed mutants N621, N621/630, N621/642, N630/642,
although the number of syncytia observed varied with
the mutant genotype (Fig. 3).
In the second assay and to enable syncytium forma-
tion to be monitored in a more quantitative way, the
339gp41 GLYCOSYLATION SITES ROLE IN HIV-1
degree of cell fusion was monitored in an adaptation of
the reporter gene assay developed by Nussbaum et al.
(1994) in which b-galactosidase is produced selectively
in fused cells by the action of T7 polymerase introduced
in trans as a result of gp160/CD4-dependent cell to cell
fusion. In our assays, envelope proteins (wild-type and
the reconstructed glycosylation site mutants) were ex-
pressed in Vero cells by vTF7-3 infection and plasmid
transfection and their fusigenic activity scored after mix-
ing with HeLaT4 cells expressing CD4 and containing
the lacZ gene under control of the T7 promoter.
Using the assay, the parental gp160 lacking gp41 gly-
cosylation (N0) displayed b-galactosidase activity levels
similar to those observed with the control samples that
had received only vector DNA while wild-type gp160
gave high b-galactosidase levels arbitrarily set at 100%
activity. Mutants in which single glycosylation sites at
N630 or N642 had been reconstructed singly displayed a
low level of activity (5.7 and 2.8% of that of the wild type,
respectively), but the level of fusion was enhanced to
23.1% of the wild-type level when both sites were recon-
structed in the same mutant (N630/642). Mutants carry-
ing a single reconstructed site at N621 displayed 6.2% of
wild-type activity, the highest for a single glycosylation
site restoration, but the addition of one further glycosy-
lation site as in mutant N621/630 increased b-galactosi-
dase activity approximately fivefold to 31% of the activity
shown by gp160WT. Similarly, when site 621 was recon-
structed with a second site at 642 the dual reconstructed
mutant showed 33.8% of wild-type activity. The data are
compared to the observation results in Table 1 and,
taken together, we conclude that reconstruction of a
single glycosylation site at position 621 is sufficient to
restore a degree of fusion activity but that activity is
enhanced substantially if at least one other site (at either
630 or 642) is also glycosylated. Single site replace-
ments at 630 or 642 did not restore fusion activity (no
observable syncytia and low b-galactosidase activity)
FIG. 1. Schematic representation of the gp41 glycosylation site reconstructions. The position of the cleavage sites (C), of the transmembrane domain
(TM), and of the recognition sites for the restriction enzymes SstI, BsmI, SalI used in the cloning are indicated. Positions of all the N-glycosylation
sites present on the gp41 molecule studied here are shown as is their presence (n) or absence (F) in the wild-type envelope.
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but restoration of the two sites together did allow fusion
activity albeit not to the degree observed in reconstruc-
tions in which the site at N621 was glycosylated.
In addition to the reconstruction of glycosylation sites
at their original location, a new single site was inserted
at position 637 in a background of N0 to assess if the
exact position of the glycosylation sites was important or
if glycan addition elsewhere in gp41 might be sufficient
for the induction of a fusion-competent gp160 conforma-
tion. In addition, the glycosylation site at 637 was made
with each of the other original reconstructed single sites
and also in combination with pairwise combinations of
sites and with all three sites (i.e., mutants N621/637,
N630/637, N637/642, N621/630/637, N621/637/642, N621/
630/637/642). As with the glycosylation site reconstruc-
tion mutants, all gp160 molecules with the site at 637
added were expressed and processed to gp120 and
gp41 although the expression level of some reconstruc-
tions varied (Fig. 2). However, when assayed in parallel
for fusion activity, all constructions carrying the added
site at 637 failed to induce syncytia (Fig. 3). Thus, the
introduction of a canonical glycosylation triplet at posi-
tion 637 in the context of N0, in the reconstructed wild-
type gp160 or in any of the intermediate glycosylation
phenotypes, prevented detectable fusion activity.
DISCUSSION
The mature envelope glycoproteins of HIV-1, gp120
and gp41, contain several conserved domains and sites
for the incorporation of N-linked sugars (Willey et al.,
1986). Such conservation indicates that these regions
are significant for the structure and function of the viral
envelope. Indeed, in a previous study we found that loss
of the three glycosylation sites in gp41 at positions 621,
630, and 642 completely abrogated Env-mediated fusion
activity. In the present study, we used our N0 mutant
lacking all three sites as the background for the con-
struction and expression of a panel of mutant gp41 en-
velope protein in which one or more of the conserved
N-linked glycosylation sites was reformed. This is in
contrast to earlier studies in which individual sites were
removed by mutagenesis. After confirming that each mu-
tant was competent for Env expression and processing,
Env-mediated cell to cell fusion was assayed to ascer-
tain the minimum glycosylation requirement for activity.
The absence of individual glycosylation sites at N621,
N630, or N642 did not substantially affect syncytium
formation and suggested that glycosylation of two of the
conserved sites was sufficient in promoting efficient syn-
cytium formation. These results contrast with those re-
ported by Dash et al. (1994) and Cao et al. (1993) who
concluded that the single N-glycosylation at position 642
was indispensable for syncytium formation although they
are in accordance with the data published by Dedera et
al. (1992) and Lee et al. (1992). Our inspection of these
reports suggests that the conflicting results could be
explained by the particular amino acid substitutions in-
troduced. As in our studies, Dedera et al. (1992) modified
glycosylation sites by the substitution of Asn for Gln
while, in contrast, Dash et al. (1994) substituted Asn for
Ser and Cao et al. (1993), Thr for Ala or Met. In these
cases the biosynthetic pathway defect, which probably
reflects a conformational change of the precursor glyco-
protein, could be a result of amino acid substitution
rather than a result of loss glycosylation at these sites
particularly as their location is in a structurally important
helix (Lu et al., 1995, and see below). A similar explana-
tion would apply to our introduction of a new glycosyla-
tion site at position 637, a position we gauged from the
early gp41 model of Gallaher et al. (1989) to be situated
on the surface of the protein and therefore to cause
minimal general disruption. All Env reconstructions in-
volving N637, including those in which the glycosylation
FIG. 2. Expression of Env glycosylation mutants. Following infection
with vaccinia virus vTF7-3 and transfection with plasmids encoding
gp160 (wild-type and mutants), cell lysates were analyzed by SDS–10%
PAGE and then Western blotted. Staining was performed with the
monoclonal antibody NEA9303. The positions of gp160 and gp41 are
indicated on the right and those of molecular weight (MW) markers on
the left. The control lane, V, contained cells infected with vTF7-3 alone.
341gp41 GLYCOSYLATION SITES ROLE IN HIV-1
sites identified as sufficient for fusion were also restored,
failed to induce syncytia in HeLaT4 cells although they
were expressed and cleaved.
Our data show that N0 expressed in this system is
cleaved (cf. Fig. 2) and contrasts with our previous find-
ing of inefficient Env cleavage in the absence of gp41
glycosylation (Fenouillet et al., 1993). This discrepancy is
probably explained by the higher levels of Env expres-
sion achieved through the use of a recombinant vaccinia
virus in the former studies rather than the plasmid trans-
fection system used here. The accumulation of un-
cleaved Env precursor in vaccinia-Env-infected cells has
been reported elsewhere (Hallenberger et al., 1992).
There have been no reports of the biological activity of
gp41 carrying only one glycosylation site but our data
suggest that, of all the sites under test, restoration of the
conserved site at position 621 allowed a measurable
degree of fusion activity albeit at significantly reduced
rates compared with wild-type gp160 or molecules with
at least two reconstructed sites. In addition, the restora-
FIG. 3. Syncytium formation by each reconstructed glycosylation site mutant following expression in HeLaT4 cells. Cell monolayers (105) were
infected with vTF7-3 and then transfected with 0.5 mg of Env encoding plasmid DNA (wild-type or mutant). The plates were sealed and incubated for
18 h before photography.
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tion of N621 was the only single site reconstruction that
showed syncytia observable by light microscopy (Fig. 3).
Nonetheless, restoration of fusion to any substantial de-
gree (typically 25–33% of the wild-type level) only oc-
curred when two glycosylation sites were reconstructed.
This observation would be consistent with the hypothe-
sis put forward by Fenouillet et al. (1994) that glycans
may act in concert to provide a molecular ‘‘padding’’
beneficial for the adoption of a functional Env conforma-
tion and that, as long as sufficient glycans are present,
their exact position is of secondary importance.
Recently, structural data on regions of HIV gp41 have
become available. Peptides representing amino acid
540–590 and 624–666 have been inferred to be a-helices
that exist in an antiparallel configuration within a trimer
of gp41 molecules (Lu et al., 1995). The central regions of
each peptide have been confirmed in this configuration
by direct crystallography (Chan et al., 1997) and the
structure has been likened to the fusion domains of
Moloney Leukemia virus and of Influenza virus. Two of
the sites studied here (630 and 642) can be modelled
directly into this structure and the third (621) lies very
close to the amino terminus of the latter peptide, allow-
ing a good approximation of its position. Moreover, he-
lical wheel representations of the peptide 624–666 (Lu et
al., 1995) place the two sites at 621 and 642 on the outer,
solvent accessible, surface of the trimer while site 630
appears less exposed (Fig. 4). It is noteworthy that the
reconstruction mutant 621/642 gave the highest recovery
of fusion activity recorded for any of the dual reconstruc-
tions. We suggest therefore that the role of the glycans,
which are hydrophilic and relatively bulky, in gp41 may
be to help stabilize the fusion active domain of gp41
either during Env intracellular transport or during virion
entry or both.
In summary, our results confirm and extend previous
findings that glycosylation of the gp41 domain of HIV-1
Env is required for biological activity. While a single
glycosylation site at position 621 allows very limited
fusion, activity is restored to near wild-type levels when
two sites are occupied. The position of the sites on the
available structure of gp41 offers a plausible explanation
of their mode of action and contributes to the overall
understanding of the gp41-induced fusion mechanism.
MATERIALS AND METHODS
Construction of the mutated Envs
The HIV-1BH10 wild-type env gene was cloned into
pGEM-T (Promega) downstream of the T7 RNA polymer-
ase promoter (clone WT). Similarly the HIV-1BH10env se-
quence lacking the three conserved glycosylation sites
(clone pTG8134) at nucleotides 7426, 7453, and 7489 in
gp41 (corresponding to Asn 621, 630, and 642, respec-
tively), as described (Fenouillet et al., 1993), was also
cloned into pGEM-T (clone NO) (Fig. 1). Clone N0 was
used as the background for the construction of a set of
mutants reintroducing one, two, or three of the con-
served glycosylation sites described above. Similarly, it
was used to generate mutants presenting a new site at
position 637. All mutants were produced by an overlap-
ping polymerase chain reaction method (PCR) and se-
quenced prior to use (Sanger et al., 1977).
Mutant N642 was reconstructed using the forward
primer 59ATTTGGAATGCCATGACCTGGATGGAGTGGG-
ACAGAGAAATTAACAATTACAC39 and the reverse primer
TABLE 1
Cell Fusion Quantitation Using Microscopy and the
b-Galactosidase Assay
Construct
Syncytia
formation
b-galactosidase activity
(% WT activity)
WT 111 100
NO 0 ,1.0
N621 1 6.2 6 2.6
N630 0 5.7 6 2.3
N642 0 2.8 6 2.7
N621/630 111 31.1 6 7.1
N621/642 111 33.8 6 6.9
N630/642 11 23.1 6 6.4
Note. Visual scoring of syncytia formation was done over several
fields (typified by those presented in fig. 3) by two operators. Low but
detectable syncytia were routinely scored for N621 but not for any of
the other single site reconstructions. For the quantitative assay, Vero
cells were transfected with plasmid DNA encoding Env (wild-type or
mutant) and infected with vP11gene1 while HeLaT4 cells were infected
with vCB21R-lacZ. Mixtures of cells were prepared in 96-wells plate
(2 3 105 cells/well) and incubated for 4.5 h at 37°C before assay. The
percentage of cell fusion was scored by measuring b-galactosidase
activity in detergent cell lysates and the results are representative of
the data obtained in three separate experiments after normalizing for
the relative Env expression level. Each experiment was done at least in
duplicate. Numbers represent mean values (6 standard error) after
subtraction of background b-galactosidase activity seen with Vero cells
transfected with vector only.
FIG. 4. The glycosylation sites at positions 621, 630, and 642 drawn
in relation to the model of part of gp41 presented by Lu et al. (1995). The
difference in a-helix thickness is an aid to distinguish the two helices
and is of no other significance. Similarly, the carbohydrate side chains
shown, which are only added to a single gp41 domain, are for illustra-
tion only and do not represent known structures.
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160R4 59ACGCGTCGACTTATAGCAAAATCCTTTCCAAG-
C39 to generate a 720-bp fragment flanked by unique
restriction sites BsmI at the 59 end and SalI at 39 end. The
forward primer incorporated base changes to mutate Gln
to Asn in the glycosylation sites at position 642; the
introduced Asn site is underlined. Mutant N637, with
glycosylation site at position 637, and the double mutant
N637/642, with two glycosylation sites at positions 637
and 642, used the forward primers 59ATTTG-
GAATGCCATGACCTGGATGGAGTGGAACAGAACAA-
TTAACCAATACAC39 and 59ATTGGAATGCCATGA-
CCTGGATGGAGTGGAACAGAACAATTAACAATTACAC39,
respectively. Amplification conditions were 10 ng of tem-
plate DNA, 30 pmol of each primer, and 25 cycles at
95°C, 1 min; 65°C, 1 min; 72°C, 2 min. DNA fragments
generated by PCR were cloned directly into pGEM-T,
then digested with BsmI and SalI, and ligated into simi-
larly digested clone N0. The obtained mutants were
named N642, N637, N637/642, respectively (Fig. 1).
Mutants presenting the glycosylation site in position
621 were obtained by PCR with the forward primer 160B
59CCGGGAGCTCATGAGAGTGAAGGAGAAA39 and the
reverse primer 59GGTCATGGCATTCCAAATCTGTTCCA-
GAGATTTATTACTCCAACTAGCGTTCCA39 to generate a
1900-bp fragment from the 59 end of the gp160 gene
flanked by unique restriction sites SstI at the 59 end and
BsmI at 39 end. The reverse primer also incorporated
base changes for the Gln to Asn change in the glycosy-
lation site at position 621. The amplification conditions
were as described above, except the annealing temper-
ature was 45°C for 1 min. DNA fragments generated by
PCR were cloned into pGEM-T, digested with SstI and
BsmI and then ligated into similarly digested mutants N0,
N642, N637, or N637/642. The obtained mutants were
named N621, N621/642, N621/637, N621/637/642, re-
spectively (Fig. 1).
Mutants with a glycosylation site at position 630 were
constructed by PCR generation of two env fragments incor-
porating the carbohydrate change, followed by PCR to re-
construct the full gene. The first PCR used the forward
primer 160B and the reverse primer 59CCACTCCATCCAG-
GTCATGTTATTCC39 to generate a 1900-bp fragment with
the Asn at position 630. In the second PCR, the forward
primer 59GGAATAACATGACCTGGATGGAGTGG39 and the
reverse primer 160R4 were used to generate a 720-bp
fragment with an Asn at position 630. The amplification
conditions were the same as above and used different
template DNA (NO, N621, N642, N621/642, N637, N621/637,
or N621/637/642). These two PCR fragments were purified
and used to product the full-length cDNA of gp160 with the
appropriate mutations. The amplification conditions were
30 ng of PCR products and seven cycles at 95°C, 1 min;
45°C, 5 min; 72°C, 2 min, followed by the addition of 30
pmol of each primers 160B and 160R4 and an additional 20
cycles at 95°C, 1 min; 45°C, 3 min; 72°C, 2 min. The PCR
products were purified and cloned into pGEM-T down-
stream of a T7 RNA polymerase promoter. The correspond-
ing mutants were named N630, N621/630, N630/642, N621/
630/642 (WT), N630/637, N621/630/637, or N621/630/637/
642 (Fig. 1).
Env expression
HeLaT4 (CD41) cells (Maddon et al., 1986) were cul-
tured in RPMI 1640 supplemented with 1% glutamine, 1%
penicillin and streptomycin, 10% fetal bovine serum
(FBS), and 200 mg/ml of geneticin (Gibco) to maintain
selection for CD4 expressing cells. For expression of Env
protein they were seeded in 24-well plates at 105 cells/
well and, after 24 h, they were infected for 1 h with vTF7-3
(106 PFU/well), a recombinant vaccinia virus expressing
T7 polymerase (Fuerst et al., 1986; Weisz and Machamer,
1994). The cells were then transfected with each of the
Env mutant clones described above using DOTAP (Boeh-
ringer–Mannheim) in RPMI 2.5 overnight after which time
the culture medium was supplemented with 10% FBS
and incubation continued for 72 h.
Cells were harvested directly into lysis buffer (100 mM
Tris–HCl, 20% glycerol, 6% SDS, 10% b-mercaptoethanol,
0.2% bromophenol blue). The lysates were heated at
95°C for 15 min and vortexed for 2 min before analysis by
10% SDS–PAGE. Antigen was detected by Western blot-
ting using an anti-HIV-1 gp41 monoclonal (NEA-9303,
DuPont NEN) followed by detection using BM chemilu-
minescence (Boehringer–Mannheim).
Syncytium formation assay
HeLaT4 cells grown in 24-wells plate were infected
and transfected as described above. Eighteen hours
later, cultures were examined by microscopy and the
syncytia scored and photographed. Cultures were rou-
tinely monitored for an additional 2 days to ensure equiv-
alent development of syncytia.
b-Galactosidase cell fusion assay
The ability of each Env mutant to form syncytia was
also quantitated using the b-galactosidase reporter gene
activation assay (Nussbaum et al., 1994).
Briefly, Vero cells were cultured in RPMI 1640 supple-
mented with 1% glutamine, 1% penicillin and streptomy-
cin, 10% FBS. Near-confluent monolayers of Vero cells
were cultured in 60 mm diameter tissue culture plates
and transfected with Env-expression DNAs as described
above. After 4 h at 37°C, the recombinant vaccinia virus
vP11gene1, encoding T7 RNA polymerase (Alexander et
al., 1992), was added (m.o.i. 10) and plates were incu-
bated for 1 h. HeLa T4 cell monolayers were infected
with the recombinant vaccinia virus vCB21R-lacZ, con-
taining the lacZ gene linked to the T7 promoter (Alkhatib
et al., 1996) for 1 h. The cells were detached using
trypsin–EDTA (Gibco BRL), washed once, and resus-
pended in RPMI 2.5 to a density of 2.5 3 105/ml. The
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suspensions were incubated at 31°C overnight to allow
recombinant protein synthesis.
Each cell population was washed once and sus-
pended in RPMI 2.5 supplemented with cytosine arabi-
noside (40 mg/ml) at a density of 106 cells/ml. Replicate
mixtures of each cell type were dispensed into 96-wells
flat-bottom tissue culture plates (2 3 105 cells/well; 0.2
ml final volume). After 4.5 h at 37°C, cells were lysed by
0.5% (vol/vol) Nonidet P-40 and b-galactosidase activity
was quantitated by mixing 50 ml of each lysate with 50 ml
of 23 substrate solution (16 mM chlorophenol red–b-
galactopyranoside (CPRG from Boehringer–Mannheim),
0.12 M Na2HPO4, 0.08 M NaH2PO4, 0.02 M KCl, 0.002 M
MgSO4, 0.01 M b-mercaptoethanol) and monitoring A580.
Env expression in this assay was controlled and quanti-
tated by Western blot as above with the b-galactosidase
activity normalized to equivalent amounts of Env protein.
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